Literature DB >> 11157888

Proliferation of CECs requires dual signaling through both MAPK/ERK and PI 3-K/Akt pathways.

A Zubilewicz1, C Hecquet, J Jeanny, G Soubrane, Y Courtois, F Mascarelli.   

Abstract

PURPOSE: To analyze the intracellular signaling involved in the proliferation of choroidal endothelial cells (CECs) in vitro.
METHODS: Bovine CECs were cultured in endothelial growth medium (EGM) containing 2% fetal calf serum (FCS), 10 microg/ml bovine brain extract (BBE), and 10 ng/ml epidermal growth factor (EGF) in fibronectin-coated plates. Cells were treated with various specific pharmacologic inhibitors of the mitogen-activated protein kinase (MAPK) and of the phosphatidylinositol 3-kinase (PI 3-K) pathways to analyze signaling involved in CEC proliferation. Activation of the MAPK and PI 3-K was detected by Western blot analysis, using specific antiphosphosignaling protein antibodies.
RESULTS: FCS, EGF, and BBE were all necessary to induce optimal CEC proliferation. Individually, these three components were not mitogenic. EGM-stimulated CEC proliferation involved the activation of the Raf/mitogen extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK)/p90(RSK) cascade. Inhibition of Ras resulted in a 92% reduction of CEC proliferation, whereas inhibition of ERK1/2 activity reduced it by only 46%. The PI 3-K/p70(S6K)/Akt pathway was also stimulated during CEC proliferation, and inhibition of PI 3-K activity resulted in a 94% reduction in CEC proliferation. Inhibition of PI 3-K/p70(S6K) activities also unexpectedly inhibited ERK activity, whereas the converse was not observed, suggesting that PI 3-K acted upstream from ERK and controlled this pathway for CEC proliferation.
CONCLUSIONS: CEC proliferation involves both ERK and PI 3-K. That PI 3-K signaling is a key component in cell proliferation can be demonstrated by controlling ERK activity. These data on the molecular mechanism and signaling of CEC proliferation may have major implications for developing more selective methods for antiangiogenic and antitumoral therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157888

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Biased TAS2R Bronchodilators Inhibit Airway Smooth Muscle Growth by Downregulating Phosphorylated Extracellular Signal-regulated Kinase 1/2.

Authors:  Donghwa Kim; Soomin Cho; Maria A Castaño; Reynold A Panettieri; Jung A Woo; Stephen B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  2019-05       Impact factor: 6.914

Review 2.  CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.

Authors:  Vera Paschon; Felipe Fernandes Correia; Beatriz Cintra Morena; Victor Allisson da Silva; Gustavo Bispo Dos Santos; Maria Cristina Carlan da Silva; Alexandre Fogaça Cristante; Stephanie Michelle Willerth; Florence Evelyne Perrin; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2020-01-11       Impact factor: 5.590

3.  Isolation, culture, and characterisation of human macular inner choroidal microvascular endothelial cells.

Authors:  A C Browning; T Gray; W M Amoaku
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

4.  Inhibitory role of adiponectin peptide I on rat choroidal neovascularization.

Authors:  Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora
Journal:  Biochim Biophys Acta       Date:  2012-05-23

5.  Role of Adiponectin Peptide I (APNp1) in Age-Related Macular Degeneration.

Authors:  Connor Logan; Valeriy Lyzogubov; Nalini Bora; Puran Bora
Journal:  Biomolecules       Date:  2022-09-03

6.  Chrysin Inhibits High Glucose-Induced Migration on Chorioretinal Endothelial Cells via VEGF and VEGFR Down-Regulation.

Authors:  Zhen-Yu Liao; I-Chia Liang; Hsin-Ju Li; Chia-Chun Wu; Huey-Ming Lo; Der-Chen Chang; Chi-Feng Hung
Journal:  Int J Mol Sci       Date:  2020-08-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.